Clinical Trial Update: A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 study of visilizumab for intravenous steroid-refractory ulcerative colitis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Visilizumab (visilizumab)

Snippet

Sponsor: Facet Biotech | Conditions: Ulcerative Colitis | Phase 2, Phase 3 | Status: TERMINATED